# Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients

> **NCT00243529** · PHASE1,PHASE2 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 64 (actual)

## Conditions studied

- Melanoma Stage III or IV

## Interventions

- **BIOLOGICAL:** autologous dendritic cell vaccine

## Key facts

- **NCT ID:** NCT00243529
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2009-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243529, "Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00243529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*